GAA
VERV

Green Alpha Advisors’s Verve Therapeutics VERV Stock Holding History

Green Alpha Advisors’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50,016
Closed -$562K – 109
2025
Q2 		$562K Sell
50,016
-4,476
-8% -$25.5K 0.54% 60
2025
Q1 		$249K Buy
54,492
+25,054
+85% +$168K 0.27% 90
2024
Q4 		$166K Buy
29,438
+3,840
+15% +$21.7K 0.13% 131
2024
Q3 		$124K Buy
25,598
+6,165
+32% +$35.8K 0.1% 133
2024
Q2 		$94.8K Sell
19,433
-5,507
-22% -$34.6K 0.08% 132
2024
Q1 		$331K Buy
24,940
+2,574
+12% +$34.1K 0.24% 118
2023
Q4 		$312K Sell
22,366
-2,259
-9% -$28K 0.22% 130
2023
Q3 		$327K Buy
+24,625
New +$397K 0.25% 120

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Green Alpha Advisors's VERV Position: Q3 2025 in Review

Green Alpha Advisors sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 50,016 shares — an estimated $562K sold.

Green Alpha Advisors first reported a position in VERV in Q3 2023 and held it in 8 quarters. The position peaked at $562K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Green Alpha Advisors reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Green Alpha Advisors sold 50,016 Verve Therapeutics shares in Q3 2025, an estimated $562K.
  • Green Alpha Advisors first reported a position in Verve Therapeutics in Q3 2023 and held it in 8 quarters.
  • Green Alpha Advisors's Verve Therapeutics position peaked at $562K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Green Alpha Advisors's 13F filing for Q3 2025, filed 15 Oct 2025.